Oslo, 30 August 2016.
Please find enclosed the financial report and presentation for second quarter 2016.
Highlights
- Granted Orphan Drug Designation of fimaporfin for treatment of bile duct cancer in EU
- Commissioned independent expert evaluation of the early promising response data - results expected Q3 2016
- Lancet Oncology publication of the fimaporfin (Amphinex) first-in-man phase I study - with independent expert commentary
- fimaVacc ready for clinical validation - a major milestone towards potential commercialization
- Initiated first research collaboration with commercial entity for fimaVacc
A presentation will be held today, Tuesday 30 August 2016, at Oslo Cancer Cluster Innovation Park.
Time: Tuesday August 30 2016, 09.00-10.00 hrs.
Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo.
Kind regards,
Per Walday
CEO
Email: pw@pcibiotech.no
Mobil: +47 917 93 429
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
